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Embolization of the left gastric artery with the intent of decreasing hunger, termed bariatric embolization, has experienced a recent surge of attention in
the literature and at medical conferences. This endovascular treatment for obesity has demonstrated promising data as a potentially new and effective
minimally invasive treatment for obesity. The goal of this review article is to discuss the background, rationale, and existing data on this new topic.
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Bariatric embolization, also known as left gastric artery embo-
lization, is a recently introduced endovascular image-guided pro-
cedure aimed at treating obesity.1 This procedure entails
percutaneous transarterial particle embolization of the gastric
fundus arterial supply, which is the site of the highest concentra-
tion of ghrelin-secreting cells in the body. By doing so, it is hy-
pothesized that the intentionally induced ischemia in the gastric
fundus will result in depressed serum ghrelin levels, which may
decrease hunger, decrease food intake, and thereby induce weight
loss. The goal of this review article is to discuss the background,
rationale, and existing data on this new and burgeoning topic.
Obesity
In 1997, the World Health Organization designated obesity as a
global epidemic, marking the ﬁrst time in history that a noninfec-
tious malady has been labeled as an epidemic.2 In 2008,>1.4 billion
adults were overweight, with a body mass index (BMI) of 25. Five
hundred million were obese, with a BMI of  30.3 Thus, 11% of the
world’s population was classiﬁed as obese. The rate of obesity is
growing, with an incidence that has nearly doubled since 1980.
Obesity is ranked as the ﬁfth leading risk for mortality globally.3
Obesity has been strongly linked to numerous comorbidities,
including type II diabetes, hyperlipidemia, hypertension, obstructive
sleep apnea, heart disease, stroke, asthma, cancer, and depression.4
The link is actually strong – for example, the risk of diabetes in-
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only mild obesity. In aggregate, these obesity-related comorbidities
have been reported to be responsible for>2.5milliondeaths per year
worldwide. Not surprisingly, life expectancy is profoundly affected
by obesity. For example, a 25-year-old morbidly obese man can
expect a 22% reduction in lifespan.5 In fact, an expert panel convened
by the National Institutes for Health stated that for the ﬁrst time in
history, the steadily improvingworldwide life expectancy could level
off or even decline within the ﬁrst half of this century, speciﬁcally as
the result of the increasing prevalence of obesity.6
The fundamental cause of obesity is an energy imbalance, with
more calories being consumed than expended. The global rise in
obesity can be attributed at least in part to the increased intake of
high-calorie and high-fat foods and a decrease in physical activity
related to the increasingly sedentary lifestyles resulting from
modernization and automation. However, numerous additional eti-
ologies and pathologies are also known to be responsible for obesity.
Regulation of hunger
The hormonal regulation of hunger is complex, and is primarily
governed by hunger-inhibiting hormones.7 Mechanical and
chemical factors associated with meals stimulate enteroendocrine
cells, resulting in signals transmitted neutrally through vagal
nerves and/or circulating hormones. The end result is modulation
of hunger in the central nervous system. Short-term hunger mod-
ulation in response to meals is largely due to cholecystokinin.
Longer-term regulation of energy balance and weight is controlled
largely by the effects of insulin and leptin. Although >40 hormones, NC, USA
t of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710, USA.
on. Published by Elsevier. All rights reserved.
Charles Y. Kim et al. / Bariatric embolization for treatment of obesity 81have been shown to inhibit appetite, only ghrelin has been shown
to stimulate appetite.7
Ghrelin
Ghrelin is a peptide hormone that is secreted primarily from the
gastrointestinal tract, with the highest concentration in the fundus
of the stomach, with progressively decreasing concentrations in the
small and large intestines. Ghrelin was ﬁrst identiﬁed and reported
in the literature in 1999 as an endogenous ligand for the growth
hormone secretagogue receptor.8 Additionally, ghrelin directly
stimulates appetite and induces positive energy balance, resulting
in body weight gain. Ghrelin is also expressed in the pancreatic
islets, hypothalamus, and pituitary gland. In addition to stimulating
appetite, ghrelin has also been shown to increase circulating
growth hormone, adrenocorticotropic hormone, cortisol, prolactin,
and glucose.9 Given the relatively recent discovery of ghrelin and
incomplete understanding of its functional role, it likely has addi-
tional effects on other hormones and functions. Due to the unique
nature of this hormone and its effect on appetite, multiple ap-
proaches to modulate ghrelin production have been attempted.
Although various reports of ghrelin suppression have been
described, none to date have been clinically practical, including
intraventricular and large intraperitoneal delivery of ghrelin an-
tagonists in rats, as well as a ghrelin vaccine.10–13
Gastric distribution
The detailed distribution of ghrelin-expressing cells has been
reported in two separate studies.14,15 Although Kim et al14 analyzed
gastric specimens from patients with gastric cancer undergoing
total gastrectomy, Goitein et al15 analyzed resected gastric speci-
mens from patients undergoing sleeve gastrectomy, which entails
vertical resection of most of the stomach volume, including the
entire fundus, most of the gastric body, and part of the antrum. In
both studies, polymerase chain reaction analysis of ghrelin mRNA
and immunostaining for ghrelin-expressing cells were performed
throughout the resected specimen. In both studies, ghrelin mRNA
and ghrelin-expressing cells were identiﬁed throughout the entire
stomach; however, the concentrations of ghrelin mRNA and
ghrelin-expressing cells were statistically highest in the gastric
fundus, and lowest in the gastric antrum. Kim et al14 reported a
ghrelin/actin mRNA ratio of 0.78 in the fundus, 0.20 in the body,
and 0.07 in the antrum, reﬂecting a 10-times higher ghrelin con-
centration level in the fundus compared to the antrum. Goitein
et al15 similarly reported a ghrelin/ribosomal mRNA ratio of 0.043,
0.026 and 0.015, respectively, which is an approximately three-
times higher level in the fundus than antrum.
Treatment options for obesity
Diet and exercise regimens, while effective, have been shown to
be difﬁcult to maintain in the long term.16 Plasma ghrelin levels
have been shown to rise sharply shortly prior to meals, which
correlates with hunger that occurs just prior to consuming meals.17
Conversely, ghrelin levels fall shortly after each meal, which cor-
relates to the satiation of hunger after consuming food. Diet regi-
mens to induce weight loss have been shown to be difﬁcult to
sustain, due to the increase in hunger.16 Thus, it may not be sur-
prising that dieting induces a 24% increase in the 24-hour ghrelin
proﬁle (P ¼ 0.006).17 This elevated ghrelin secretion may therefore
be a reason why dieting is so difﬁcult to sustain in the long term.
Pharmacological modulation of hunger would be perhaps the
ultimate means of controlling appetite and weight. Despite great
efforts in this area, current pharmacotherapeutics can achieve onlymodest levels of weight loss with a range of 2.0–6.5 kg of sustained
weight loss.17
Although bariatric surgery has proven to result in substantial
degrees of sustained weight loss, the surgical risk in this patient
population is signiﬁcant. Alterations in ghrelin levels also occur
with bariatric surgery. After gastric banding, there has been shown
to be a 27% increase in serum ghrelin levels, which may be unde-
sirable if patients experience increased hunger.18 The results with
roux-en-Y gastric bypass are somewhat controversial. Although
some studies have demonstrated a decrease in serum ghrelin,
others have shown ghrelin levels to be unchanged.19–21 However,
with sleeve gastrectomy, the levels of serum ghrelin have been
shown in multiple studies to be markedly decreased byw60%.20,21
In fact, ghrelin depression has been shown to be signiﬁcantly
depressed even as far as 5 years post-surgery.22 Considering that
the majority of the gastric fundus is removed during sleeve gas-
trectomy, there would certainly be a loss of a large proportion of
ghrelin-secreting cells. Many have postulated this as one of the
primary reasons why sleeve gastrectomy is themost effective of the
bariatric surgeries, and conversely, a reason why surgeries that
have no gastric tissue resection, such as gastric banding, have poor
efﬁcacy.
Gastric artery chemical embolization
The initial discovery that introduced the concept of destruction
of ghrelin-producing cells by minimally invasive catheter-directed
techniques was reported by Arepally et al23 in 2007. In this pilot
study, the authors demonstrated that infusion of sodium morrhu-
ate, a varicose vein sclerosant, into the left gastric artery of swine
resulted in elevated serum ghrelin levels with low doses, but
depressed serum ghrelin levels at moderate doses. Notably, at high
doses, death resulted secondary to gastric necrosis and perforation.
Arepally went on to perform gastric artery chemical embolization
(GACE) in a larger number of swine using the higher doses, with a
control arm to assess for differences in ghrelin level and weight
over a 4-week period.24 Again, the serum ghrelin levels in treated
animals were shown to be signiﬁcantly depressed compared to
controls. In these growing swine, the mean weight was statistically
lower at 3 weeks and 4 weeks compared to untreated controls.
However, the mean serum ghrelin levels demonstrated a 51% in-
crease at 4 weeks, suggesting that the effect may be transient.
Bariatric embolization in a porcine model
The use of sodium morrhuate, while promising in the initial
studies, would be difﬁcult to translate to use in humans. This long-
used sclerotherapy agent is used to induce direct damage to the
endothelium of varicose veins. As a liquid agent, control of the
distribution of ﬂow can be difﬁcult to control. The appropriate
amount to administer would also be difﬁcult to ascertain given
variability in stomach size and vascularity. A well-described
complication of sodium morrhuate use in venous sclerotherapy is
inadvertent ﬂow to the lungs, which causes pulmonary arterial
injury and even respiratory failure.25 Even more worrisome is its
ability to induce transmural necrosis and perforation when infused
into the gastric arteries.23
Rationale
In an effort to destroy ghrelin-secreting cells in the gastric
fundus using an agent that is benign, more controllable, and
potentially easily translatable to human trials, our research group
investigated the effect of ischemia by means of particle emboliza-
tion of the gastric fundus as a method to potentially impair the
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initial results by Arepally et al23 were achieved using a highly toxic
substance, therefore, we sought to maximize the amount of
ischemic damage, and thus used the smallest commercially avail-
able particles (40 mm diameter calibrated microspheres) and
embolized all identiﬁable arteries supplying the gastric fundus.
Results
Over the 8-week study, the ghrelin levels in animals undergoing
bariatric embolizationwere signiﬁcantly lower compared to control
animals that underwent a sham procedure (P ¼ 0.004). The
resulting weights at the end of the study were also signiﬁcantly
lower in treated animals (P ¼ 0.025). While the results of particle
embolization of the gastric fundus were similar to the results with
chemicals of Arepally et al,23 there were no animals with trans-
mural necrosis or perforation. Endoscopic evaluation at 1 week and
histopathological evaluation of postmortem specimens did reveal
that half of all animals had evidence of healing ulcers. Notably, none
were particularly large and all were in a state of healing. Although
all animals undergoing bariatric embolization did show evidence of
gastritis, 83% of control animals undergoing a sham procedure also
had evidence of gastritis. It is known that the stress of captivity in a
new environment, as well as general anesthesia, is sufﬁcient to
induce gastritis and ulcers in swine. Of note, 79% of swine raised in
farms have an ulcer or pre-ulcer changes.26
Histopathological evaluation of the explanted gastric mucosa
was an important goal of our studies, to determine the actual
sequelae of bariatric embolization.27 Although there was a trend
towards increased ﬁbrosis in the gastric fundus of treated animals,
it did not reach statistical signiﬁcance. However, analysis of the
ghrelin-secreting cell density showed a signiﬁcantly lower cell
density in treated animals compared to controls (P ¼ 0.03). This
ﬁnding importantly established that the ischemia induced by par-
ticle embolization of the stomach is sufﬁcient to destroy ghrelin-
secreting cells, without causing profound architectural destruc-
tion of the gastric wall.
Given the natural inclination of the body towards homeostasis,
it is a concern that upregulation of ghrelin-secreting cells eventu-
ally occurs elsewhere in the body, thus returning serum ghrelin
levels to baseline over time. In order to explore this phenomenon,
all animals in our study also underwent evaluation of the duo-
denum, since this is the second-richest source of ghrelin-secreting
cells. The ghrelin-secreting cell density was demonstrated to be
equivalent, comparing the treated gastric fundus to the untreated
duodenum (P ¼ 0.89), although the time interval was relatively
short at 8 weeks.
In additional studies, we sought to determine whether gastro-
protective agents could mitigate the risk of ulceration, by admin-
istering sucralfate and a proton-pump inhibitor to animals prior to
and after bariatric embolization.28 We also hypothesized that
embolization of a greater number of embolized arteries would
affect the extent and severity of ulceration. In these additional
experiments, neither gastroprotective agents nor number of ar-
teries embolized prevented ulceration. Thus, gastric ulceration may
be an innate risk of bariatric embolization, although it must be kept
inmind that the particle size may be related, and that swinemay be
at higher risk than humans for this side effect.
Animal model limitations
The animals used in this study were young, growing pigs,
approximately 10–14 weeks old, weighing 30–47 kg. This repre-
sents a different physiological circumstance when compared to
obese adults that have stopped growing but have excessive caloricintake. Thus, weight gain in these growing pigs was due to not only
adipose tissue, but more signiﬁcantly to muscle, bone, and organ
growth. Thus, the results attained in swine may not be generaliz-
able to humans. That being said, perhaps it is more difﬁcult to
impair growth in growing pigs than to induce weight loss in obese
adults. Swine were the choice of animals for this study due to the
high prevalence of swine in the literature for analyzing ghrelin
levels, and their anatomy that is similar in size and conﬁguration to
humans.
Targeting of the fundus
Another limitation of our model for the accurate targeting of the
gastric fundus is its nondiscrete arterial supply. In humans, multi-
ple arteries supply the gastric fundus, including the left gastric
artery, short gastric arteries, and left gastroepiploic artery. All of
these arteries interconnect with each other, as well as the arteries
that supply the body and antrum of the stomach, including the
right gastric artery, right gastroepiploic artery, and gastroduodenal
artery. Thus, depending on the ﬂow dynamics, infusions of particles
or any substance into any one of these arteries could have a variable
amount of fundal embolization and would almost certainly have
some degree of embolization of the gastric body and antrum. Due to
the extensive interconnections, non-target embolization of the
spleen, pancreas, liver, and duodenum are at-risk organs.
Bariatric embolization in a canine model
Contemporary to our study, Bawudun et al29 conducted a
similarly designed study in a canine model. However, in addition to
a particle embolization treatment group, a chemical embolization
group (bleomycin plus lipiodol) was also used. Bleomycin is a
chemotherapeutic agent that causes strand breaks in DNA and is
also used as a chemical sclerosant for pleurodesis. The particle
embolization group was treated with 500–700 mm polyvinyl
alcohol (PVA) particles.
Over an 8-week period, the authors reported that plasma
ghrelin levels and body weight were signiﬁcantly decreased in both
treatment groups compared to controls. Several additional impor-
tant parameters were analyzed. The abdominal body fat was
quantiﬁed using computed tomography performed pre-
procedurally and at 8 weeks. Both visceral and subcutaneous fat
were quantiﬁed. The subcutaneous fat was signiﬁcantly decreased
in both treatment groups, whereas visceral fat was not. Gastric
peristalsis was assessed at 8 weeks with a barium study of the
stomach, with the conclusion that the gastric peristalsis appeared
normal. Histopathological analysis demonstrated no difference in
parietal cell structures comparing treated animals to controls. No
gastric ulcers were identiﬁed.
Two important differences in the model are worth highlighting,
compared to the swine model studies. First, the animals were on
average 2 years old, and thus beyond the active growth stage. Thus,
this model would more closely approximate the use of bariatric
embolization in human adults, and the signiﬁcant decrease in the
amount of subcutaneous fat over 8 weeks is important and highly
promising. The second and perhaps more important ﬁnding is that
no gastric ulcers were detected in this study. At least two technical
factorsmay be responsible for this ﬁnding. In this study, the authors
used larger particles for embolization, measuring 500–700 mm,
whereas in the swine study, 40-mm particles were used. The other
factor may be that only one artery, that is, the left gastric artery, was
treated in the canine study, whereas all four arteries supplying the
gastric fundus were treated in the swine study. These factors may
be useful for determining the optimal technique by which to
perform bariatric embolization safely and efﬁcaciously.
Table 1 Weight and ghrelin trends over time for the 5 patients in the ﬁrst-in-
man pilot study.31
Body mass
index
Weight
(kg)
Weight
change (%)
Ghrelin
change
Baseline 43 128
1 mo 38 115 10 29
3 mo 37 111 13 36
6 mo 35 108 16 18
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In a retrospective fashion, Oklu et al30 presented the results of a
single-institution cohort study of 15 patients who underwent
transcatheter embolization of the left gastric artery for the indi-
cation of gastric hemorrhage, in comparison with a cohort of 18
age-matched patients who underwent embolization of any non-left
gastric artery for treatment of upper gastrointestinal hemorrhage.
Analysis of resultant weights over the subsequent 3 months
revealed a 7.9% mean decrease in body weight for patients under-
going left gastric artery embolization compared to a mean 1.2%
decrease in body weight for those undergoing embolization of a
different upper gastrointestinal artery (P ¼ 0.001). Embolic agents
included particulate agents, coils, or a combination.
Kipshidze et al31 reported the results of a ﬁrst-in-human pro-
spective study of left gastric artery embolization in ﬁve patients. In
this series, patients underwent embolization of the left gastric ar-
tery with 300–500-mm microspheres. Three patients reported
transient abdominal pain. Endoscopy performed in all patients at 1
week post-procedure revealed no signiﬁcant abnormalities. The
mean weight, body mass index, and ghrelin levels were decreased
at 1 month, 3 months and 6 months post-procedure (Table 1).
Future directions
In conclusion, the concept of an endovascular treatment for
obesity has demonstrated promising preliminary data in animals
and humans. However, the number and power of these studies is
still somewhat marginal, and thus additional preclinical studies are
needed to elucidate the mechanisms of this procedure. However,
given the extremely complex physiology and mechanisms affecting
appetite, weight gain, and weight loss, ultimately human trials are
crucial prior to routine clinical use. To that end, multiple human
trials have been initiated in multiple countries. Although primary
efforts in these clinical trials were aimed at demonstrating safety,
proving efﬁcacy in terms of ghrelin levels, hunger and weight loss
were also important components of these clinical trials. Perhaps
more importantly, the duration of any effects will be a crucial factor
in determining the future potential of this promising therapy. Once
safety and basic efﬁcacy are shown in further preliminary clinical
trials, a full randomized clinical trial comparing bariatric emboli-
zation to various other treatments of obesity is destined to take
place. If proven effective and safe, this endovascular method for
treatment of obesity has great promise for playing a pivotal role in
the treatment of one of the biggest epidemic health issues
worldwide.
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